Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors

Kohei Shitara, Kentaro Yamazaki, Takahiro Tsushima, Tateaki Naito, Nobuaki Matsubara, Morihiro Watanabe, Barbara Sarholz, Andreas Johne, Toshihiko Doi, Kohei Shitara, Kentaro Yamazaki, Takahiro Tsushima, Tateaki Naito, Nobuaki Matsubara, Morihiro Watanabe, Barbara Sarholz, Andreas Johne, Toshihiko Doi

Abstract

Objectives: Tepotinib (MSC2156119J) is an oral, potent and highly selective small molecule mesenchymal-epithelial transition factor (MET) inhibitor for which the recommended Phase II dose of 500 mg once daily has been defined, based on the first-in-man trial conducted in the USA and Europe. We carried out a multicenter Phase I trial with a classic `3 + 3' design to determine the recommended Phase II dose in Japanese patients with solid tumors (NCT01832506).

Methods: Patients aged ≥20 years with advanced solid tumors (refractory to standard therapy or for whom no effective standard therapy was available) received tepotinib at 215, 300 or 500 mg once daily in a 21-day cycle. Occurrence of dose-limiting toxicities during cycle 1 was used to determine the maximum tolerated dose. Efficacy, safety and pharmacokinetics were also evaluated to support the dose assessment.

Results: Twelve patients were treated. Tepotinib was generally well tolerated with no observed dose-limiting toxicities; treatment-related adverse events were mainly grades 1-2. The tolerability profile of tepotinib was similar to that observed in non-Japanese populations. Pharmacokinetics in Japanese and Western patients was comparable. One patient with gastric cancer and one patient with urachal cancer had stable disease of ≥12 weeks in duration. The observed safety profile and pharmacokinetics are comparable with those in patients from the USA and Europe, and the recommended Phase II dose of tepotinib in Japanese patients was confirmed as 500 mg once daily.

Conclusions: These results, including initial signals of antitumor activity, support further development of tepotinib in Japanese patients with cancer.

Keywords: GI-stomach-Med; clinical trials; molecular diagnosis.

© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

References

    1. Cancer Information Service [Internet] Projected Cancer Statistics, 2018. 2018. Available from: (cited 30 January 2019).
    1. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009;41:89–295.
    1. Kenmotsu H, Tanigawara Y. Pharmacokinetics, dynamics and toxicity of docetaxel: why the Japanese dose differs from the Western dose. Cancer Sci 2015;106:497–504.
    1. Saijo N. The role of pharmacoethnicity in the development of cytotoxic and molecular targeted drugs in oncology. Yonsei Med J 2013;54:1–14.
    1. Arnold FL, Kusama M, Ono S. Exploring differences in drug doses between Japan and Western countries. Clin Pharmacol Ther 2010;87:714–20.
    1. Vergoulidou M. More than a decade of tyrosine kinase inhibitors in the treatment of solid tumors: what we have learned and what the future holds. Biomark Insights 2015;10:33–40.
    1. Bladt F, Faden B, Friese-Hamim M et al. . EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-met inhibitors. Clin Cancer Res 2013;19:2941–51.
    1. Bladt F, Friese-Hamim M, Ihling C, Wilm C, Blaukat A. The c-met inhibitor MSC2156119J effectively inhibits tumor growth in liver cancer models. Cancers (Basel) 2014;6:1736–52.
    1. De Silva DM, Roy A, Kato T et al. . Targeting the hepatocyte growth factor/MET pathway in cancer. Biochem Soc Trans 2017;45:855–70.
    1. Ma PC, Tretiakova MS, MacKinnon AC et al. . Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer 2008;47:1025–37.
    1. Toschi L, Cappuzzo F. Clinical implications of MET gene copy number in lung cancer. Future Oncol 2010;6:239–47.
    1. Lee SJ, Lee J, Sohn I et al. . A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma. Anticancer Res 2013;33:5179–86.
    1. Wu CW, Li AF, Chi CW et al. . Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma. Oncol Rep 1998;5:817–22.
    1. Wu YL, Soo RA, Locatelli G, Stammberger U, Scagliotti G, Park K. Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer? Cancer Treat Rev 2017;61:70–81.
    1. Pilotto S, Carbognin L, Karachaliou N et al. . Tracking MET de-addiction in lung cancer: a road towards the oncogenic target. Cancer Treat Rev 2017;60:1–11.
    1. Pilotto S, Gkountakos A, Carbognin L, Scarpa A, Tortora G, Bria E. MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy. Ann Transl Med 2017;5:2.
    1. Bouattour M, Raymond E, Qin S et al. . Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma. Hepatology 2018;67:1132–49.
    1. Reungwetwattana T, Liang Y, Zhu V, Ou SI. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the why, the how, the who, the unknown, and the inevitable. Lung Cancer 2017;103:27–37.
    1. Falchook GS, Kurzrock R, Amin HM et al. . First-in-man phase I trial of the selective MET inhibitor tepotinib in patients with advanced solid tumors. Clin Cancer Res 2020;26:1237–46.
    1. Schadt O, Blaukat A. Tepotinib In: Chackalamannil S, Rotella D, Ward SE, editor. Comprehensive Medicinal Chemistry III, 3rd edn. Oxford: Elsevier, 2017; 178–203.
    1. Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009;101:708–20.
    1. Eisenhauer EA, Therasse P, Bogaerts J et al. . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47.
    1. Koeppen H, Yu W, Zha J et al. . Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib+/−onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit. Clin Cancer Res 2014;20:4488–98.
    1. Varella-Garcia M, Diebold J, Eberhard DA et al. . EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer. J Clin Pathol 2009;62:970–7.
    1. Moosavi F, Giovannetti E, Saso L, Firuzi O. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers. Crit Rev Clin Lab Sci 2019;56:533–66.
    1. Ryoo B-Y, Ren Z, Kim T-Y et al. . 621PD: a phase 2 trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC). Ann Oncol 2018;29:viii205–viii70.
    1. Decaens T, Barone C, Assenat E et al. . 698P: efficacy and safety of the Met inhibitor tepotinib in patients (pts) with advanced MET+ hepatocellular carcinoma (HCC) previously treated with sorafenib. Ann Oncol 2018;29:viii205–viii70.
    1. Paik PK, Veillon R, Cortot AB et al. . 9005: Phase II Study of Tepotinib in NSCLC Patients with MET ex14 Mutations. Chicago, IL, USA. May 31–June 5: Presented at American Society of Clinical Onoclogy, 2019.
    1. Wu YL, Cheng Y, Zhou C Lu S, Zhang Y, Zhou C.. Tepotinib plus gefitinib in patients with MET overexpression and/or MET amplification, EGFR-mutant NSCLC having acquired resistance to prior EGFR inhibitor.. Lancet Respir Med 2020; In press.
    1. Wu Y-L, Zhang L, Kim D-W et al. . Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor–dysregulated non–small-cell lung cancer. J Clin Oncol 2018;36:3101–9.
    1. Choueiri TK, Plimack E, Arkenau HT et al. . Biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer. J Clin Oncol 2017;35:2993–3001.
    1. Esaki T, Hirai F, Makiyama A et al. . Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors. Cancer Sci 2019;110:1340–51.
    1. Park K, Felip E, Veillon R et al. . Tepotinib in NSCLC patients harboring METex14 skipping: cohort a of phase II VISION study. Ann Oncol 2019;30:ix22–ix3.
    1. Wolf J, Seto T, Han J-Y et al. . 9004: Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): efficacy data from the phase II GEOMETRY mono-1 study. J Clin Oncol 2019;37:9004.
    1. Seto T, Ohashi K, Sugawara S et al. . A Phase 2 Study of Capmatinib in Patients with METΔex14-mutated Advanced NSCLC (GEOMETRY mono- 1): Japanese Subgroup Analysis. Osaka, Japan: December 6–8: Presented at Japan Lung Cancer Society, 2019.
    1. Lu S, Fang J, Cao L et al. . CT031: preliminary efficacy and safety results of savolitinib treating patients with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations. Cancer Res 2019;79.
    1. Sequist LV, Han J-Y, Ahn M-J et al. . A phase 1b study of osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small cell lung cancer after progression on EGFR-tyrosine kinase inhibitors. Preprints with The Lancet [Internet]2019. Available from: (cited 9 March 2020).
    1. Drilon A, Clark JW, Weiss J et al. . Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. Nat Med 2020;26:47–51.
    1. Shimokawa M, Nosaki K, Seto T et al. . Phase II study of crizotinib in Japanese patients with advanced non- small cell lung cancer harboring a MET gene alteration: co-MET study. Ann Oncol 2019;30:ii66.
    1. Ujiie H, Tomida M, Akiyama H et al. . Serum hepatocyte growth factor and interleukin-6 are effective prognostic markers for non-small cell lung cancer. Anticancer Res 2012;32:3251–8.
    1. Tsuji T, Sakamori Y, Ozasa H et al. . Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer. Oncotarget 2017;8:71805–16.
    1. Naumnik W, Naumnik B, Niklinska W, Ossolinska M, Chyczewska E. Clinical implications of hepatocyte growth factor, interleukin-20, and interleukin-22 in serum and bronchoalveolar fluid of patients with non-small cell lung cancer. Adv Exp Med Biol 2016;952:41–9.
    1. Finocchiaro G, Toschi L, Gianoncelli L, Baretti M, Santoro A. Prognostic and predictive value of MET deregulation in non-small cell lung cancer. Ann Transl Med 2015;3:83.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever